Washington, DC (October 31, 2013) — A patient's immune response may provide better and more rapid insights into the cause, severity, and prognosis of certain bacterial infections than conventional tests, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Such an "immune fingerprint" could lead to more accurate diagnoses and more appropriate antibiotic treatment.
Approximately 11% of kidney failure patients on dialysis receive peritoneal dialysis, which is home-based. Peritoneal dialysis is generally perceived as less burdensome and as effective as clinic-based hemodialysis, but infections can cause treatment failure and even patient death if not detected early. Unfortunately, current tests for infections—which use microbiological culture methods—are slow and inefficient. Fear of infection is the major reason for patients and their doctors to opt against peritoneal dialysis despite its otherwise potential clinical benefit.
Matthias Eberl, PhD, Nicholas Topley, PhD (Cardiff University, in the UK), and their colleagues wondered whether assessing dialysis patients' immune responses might help in the diagnosis of bacterial infections. They reasoned that the human body is capable of a rapid, sensitive, and specific detection of a broad spectrum of microbes, and each pathogen stimulates unique aspects of the immune system, essentially leaving a distinct "immune fingerprint."
For their study, the researchers recorded a range of microbiological, immunological, and clinical parameters from patients on the day they were admitted to the hospital for peritonitis, an infection of the abdominal cavity. "Our goal was to identify unique fingerprints that are associated with certain groups of pathogens and/or outcome that can be exploited for diagnostic and prognostic purposes," said Dr. Eberl.
The team found that certain immune markers correlated with microbiological test results and robustly predicted the presence of infection. Furthermore, particular combinations of these biomarkers also predicted the nature of the causative pathogen—discriminating between Gram-negative and Gram-positive infections—and identified patients at an elevated risk of experiencing treatment failure.
"To our knowledge, this is the first study in acutely infected patients exploiting the notion that microorganisms display distinct sets of pathogen-associated patterns and interact with the immune system in a unique and specific manner for diagnostic purposes," said Professor Topley. In addition to potentially improving the diagnosis and treatment of peritonitis in peritoneal dialysis patients, the findings may also be applicable to other local and systemic infections. Dr. Eberl added that "the data suggest that it may be possible to develop a simple fingerprint-based point-of-care test that can be used by a general practitioner—at the bed-side or at home—to ensure that the right treatment is given to each patient."
In an accompanying editorial, Marien Fieren, PhD (Erasmus Medical Center, in The Netherlands) noted that the study "deepens our understanding of the complex, local pathogen-host interactions. Such patient-based studies are important not only from a theoretical perspective but also for the prospect of future developments that could improve diagnosis and management of the various forms of peritonitis."
Study co-authors include Chan-Yu Lin, PhD, Gareth W. Roberts, MD, PhD, Ann Kift-Morgan, PhD, and Kieron Donovan, MD.
Disclosures: The authors reported no financial disclosures.
The article, entitled "Pathogen-specific local immune fingerprints predict bacterial infection in peritoneal dialysis patients," will appear online at http://jasn.asnjournals.org/ on October 31, 2013, doi: 10.1681/ASN2013040332.
The editorial, entitled "Cloudy Peritoneal Dialysate: In Search of a Clear Cause?" will appear online at http://jasn.asnjournals.org/ on October 31, 2013, doi: 10.1681/ASN2013040332.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.